公开(公告)号：WO2008011130A8

公开(公告)日：2009-04-16

申请号：PCT/US2007016424

申请日：2007-07-20

Applicant: TAKEDA PHARMACEUTICAL ,  KITAMURA SHUJI ,  AICHER THOMAS DANIEL ,  GONZALES STEVE ,  LE HUEROU YVAN ,  PRATT SCOTT ALAN ,  NAKADA YOSHIHISA

Inventor： KITAMURA SHUJI ,  AICHER THOMAS DANIEL ,  GONZALES STEVE ,  LE HUEROU YVAN ,  PRATT SCOTT ALAN ,  NAKADA YOSHIHISA

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07D231/14 ,  C07D231/56 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08

Abstract: The present invention provides compounds represented by the formula (Ie) and the formula (If) wherein each symbol is as defined in the specification. According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.

Abstract translation: 本发明提供由式（Ie）和式（If）表示的化合物，其中每个符号如说明书中所定义。 根据本发明，这些化合物具有DGAT抑制活性，可用于预防，治疗或改善由高表达或高活化DGAT引起的疾病或病理。

公开(公告)号：WO2008011131A2

公开(公告)日：2008-01-24

申请号：PCT/US2007/016425

申请日：2007-07-20

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  KITAMURA, Shuji ,  AICHER, Thomas, Daniel ,  GONZALES, Steve ,  LE HUEROU, Yvan ,  PRATT, Scott, Alan ,  TURNER, Tim ,  NAKADA, Yoshihisa

Inventor： KITAMURA, Shuji ,  AICHER, Thomas, Daniel ,  GONZALES, Steve ,  LE HUEROU, Yvan ,  PRATT, Scott, Alan ,  TURNER, Tim ,  NAKADA, Yoshihisa

IPC: A61K31/4184

CPC classification number: C07D401/12 ,  C07D207/08 ,  C07D213/81 ,  C07D233/90 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/06 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides compounds represented by the formula (Ia) the formula (Ib) the formula (Ic) and the formula (Id) wherein each symbol is as defined in the specification. According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.

Abstract translation: 本发明提供由式（Ia），式（Ib），式（Ic）和式（Id）表示的化合物，其中各符号如说明书中所定义。 根据本发明，这些化合物具有DGAT抑制活性，并且可用于预防，治疗或改善由DGAT的高表达或高活性引起的疾病或病理。

公开(公告)号：WO2005044793A2

公开(公告)日：2005-05-19

申请号：PCT/US2004/035648

申请日：2004-10-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  GYORKOS, Albert, Charles ,  CORRETTE, Christopher, Peter ,  CHO, Suk, Young ,  TURNER, Timothy, Mark ,  PRATT, Scott, Alan ,  ASO, Kazuyoshi ,  KORI, Masakuni ,  GYOTEN, Michiyo

Inventor： GYORKOS, Albert, Charles ,  CORRETTE, Christopher, Peter ,  CHO, Suk, Young ,  TURNER, Timothy, Mark ,  PRATT, Scott, Alan ,  ASO, Kazuyoshi ,  KORI, Masakuni ,  GYOTEN, Michiyo

IPC: C07D

CPC classification number: C07D235/30 ,  C07D471/04

Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and X 1 is an oxygen, a sulfur or - NR 5 -, or formula (A"): wherein X is a nitrogen and R 6 is an optionally substituted hydrocarbyl, R 1 is an amino substituted by two optionally substituted hydrocarbyl groups, R 2 is an phenyl, Y 1 is CR 3a or a nitrogen, Y 2 is CR 3b or a nitrogen and Y 3 is CR 3C or a nitrogen, provided that one or less of Y 1 , Y 2 , and Y 3 is nitrogen, W is a bond, -(CH 2 )n-, and Z is a bond, -NR 4 -, etc.; or a salt thereof or a prodrug thereof.

Abstract translation: 提供了包含式（I）化合物的CRF受体拮抗剂：其中环A是由式（A'）表示的5元环：其中X是碳，X 1是氧， 硫或-NR 5 - ，>或式（A“）：其中X是氮，R 6是任选取代的烃基，R 1是被两个任选取代的烃基取代的氨基， R 2是苯基，Y 1是CR 3a或氮，Y 2是CR 3b或氮和Y 3是CR 3或氮，条件是一个 或更少的Y 1，Y 2和Y 3是氮，W是键， - （CH 2）n - ，Z是键，-NR 4 - ， - 等。 ;或其盐或其前药。

公开(公告)号：WO2008051533A2

公开(公告)日：2008-05-02

申请号：PCT/US2007/022472

申请日：2007-10-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED ,  ASO, Kazuyoshi ,  MOCHIZUKI, Michiyo ,  KOJIMA, Takuto ,  KOBAYASHI, Katsumi ,  PRATT, Scott, Alan ,  GYORKOS, Albert, Charles ,  CORRETTE, Christopher, Peter ,  CHO, Suk, Young

Inventor： ASO, Kazuyoshi ,  MOCHIZUKI, Michiyo ,  KOJIMA, Takuto ,  KOBAYASHI, Katsumi ,  PRATT, Scott, Alan ,  GYORKOS, Albert, Charles ,  CORRETTE, Christopher, Peter ,  CHO, Suk, Young

IPC: A61K31/4439

CPC classification number: C07D235/26 ,  C07D235/30 ,  C07D401/12 ,  C07D403/12

Abstract: There is provided a compound of the formula (1) wherein R 1 is an optionally substituted C 1-10 alkyl; R 2 is H, or a C 1-6 alkyl which may be substituted with 1 to 3 substituents; R 3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6- membered ring which may be substituted with 1 to 3 C 1-6 alkyls; R 4 is a hydrogen, a halogen, a hydroxy, a cyano, a C 1-6 alkyl or a C 1-6 alkoxy; Z is -O-, -S-, -SO-, -SO 2 -, or - NR 5 - wherein R 5 is a hydrogen or a C 1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.

Abstract translation: 本发明提供了式（1）的化合物，其中R 1是任选取代的C 1-10烷基; R 2是H或可以被1至3个取代基取代的C 1-6烷基; R 3是可以被1至5个取代基取代的5或6元芳族基团，其中5或6元芳族基团可以与5或6元环 可以被1至3个C 1-6烷基取代的环; R 4是氢，卤素，羟基，氰基，C 1-6烷基或C 1-6烷氧基; Z是-O - ， - S - ， - SO - ， - SO 2 - 或-NR 5 - ，其中R 5是 氢或C 1-6烷基; 或其盐或其前药，其具有CRF受体拮抗剂活性及其用途。

公开(公告)号：WO2005044793A3

公开(公告)日：2006-03-30

申请号：PCT/US2004035648

申请日：2004-10-27

Applicant: TAKEDA PHARMACEUTICAL ,  GYORKOS ALBERT CHARLES ,  CORRETTE CHRISTOPHER PETER ,  CHO SUK YOUNG ,  TURNER TIMOTHY MARK ,  PRATT SCOTT ALAN ,  ASO KAZUYOSHI ,  KORI MASAKUNI ,  GYOTEN MICHIYO

Inventor： GYORKOS ALBERT CHARLES ,  CORRETTE CHRISTOPHER PETER ,  CHO SUK YOUNG ,  TURNER TIMOTHY MARK ,  PRATT SCOTT ALAN ,  ASO KAZUYOSHI ,  KORI MASAKUNI ,  GYOTEN MICHIYO

IPC: C07D20060101 ,  C07D235/30 ,  C07D471/04 ,  A61K31/44 ,  A61K31/415 ,  C07D235/04 ,  C07D471/02

CPC classification number: C07D235/30 ,  C07D471/04

Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and X

Abstract translation: 提供了包含式（I）化合物的CRF受体拮抗剂：其中环A是由式（A'）表示的5元环：其中X是碳，X

公开(公告)号：WO2004017908A2

公开(公告)日：2004-03-04

申请号：PCT/US0326317

申请日：2003-08-21

Applicant: TAKEDA CHEMICAL INDUSTRIES LTD ,  YASUMA TSUNEO ,  MORI AKIRA ,  KAWASE MASAHIRO ,  KIMURA HIROYUKI ,  YOSHIDA MASATO ,  GYORKOS ALBERT CHARLES ,  PRATT SCOTT ALAN ,  CORRETTE CHRISTOPHER PETER

Inventor： YASUMA TSUNEO ,  MORI AKIRA ,  KAWASE MASAHIRO ,  KIMURA HIROYUKI ,  YOSHIDA MASATO ,  GYORKOS ALBERT CHARLES ,  PRATT SCOTT ALAN ,  CORRETTE CHRISTOPHER PETER

IPC: A61K31/00 ,  A61P19/08 ,  C07D487/04 ,  A61K

CPC classification number: C07D487/04

Abstract: There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7- membered ring; ring B is an optionally substituted 5- to 7- membered heterocyclic ring; X is CR , CR R , N or NR ; X is N or NR ; Y is C, CR or N, Z is CR , CR R , N or NR ; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and --- is a single bond or a double bond; R , R , R , R , R , R , R and R are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7- membered ring; Q is C, CR or N; R , R ,R , R and R are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X , R , R , Y and X in formula (II) and (III) as before.

Abstract translation: 提供了包含式（I）化合物的钙受体调节剂：其中环A是任选取代的5-至7-元环; 环B是任选取代的5-至7-元杂环; X 1是CR 1，CR 1 R 2，N或NR 13; X 2是N或NR 3; Y是C，CR 4或N，Z是CR 5，CR 5 R 6，N或NR 7; Ar是任选取代的环状基团; R为H，任选取代的烃基等; ---是单键或双键; R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 13独立地为H，任选取代的烃基; 或其盐或其前药。 式（II）和（III）的化合物：其中环A是任选取代的5-至7-元环; Q为C，CR 5或N; R 8，R 9，R 10，R 11和R 12独立地是H，任选取代的烃基等，或其盐。 还如前所述地在式（II）和（III）中指定X 1，R 3，R 1，Y和X 3。

公开(公告)号：WO2008051533A3

公开(公告)日：2008-06-12

申请号：PCT/US2007022472

申请日：2007-10-24

Applicant: TAKEDA PHARMACEUTICAL ,  ASO KAZUYOSHI ,  MOCHIZUKI MICHIYO ,  KOJIMA TAKUTO ,  KOBAYASHI KATSUMI ,  PRATT SCOTT ALAN ,  GYORKOS ALBERT CHARLES ,  CORRETTE CHRISTOPHER PETER ,  CHO SUK YOUNG

Inventor： ASO KAZUYOSHI ,  MOCHIZUKI MICHIYO ,  KOJIMA TAKUTO ,  KOBAYASHI KATSUMI ,  PRATT SCOTT ALAN ,  GYORKOS ALBERT CHARLES ,  CORRETTE CHRISTOPHER PETER ,  CHO SUK YOUNG

IPC: A01N43/52 ,  A61K31/415

CPC classification number: C07D235/26 ,  C07D235/30 ,  C07D401/12 ,  C07D403/12

Abstract: There is provided a compound of the formula (1) wherein R 1 is an optionally substituted C 1-10 alkyl; R 2 is H, or a C 1-6 alkyl which may be substituted with 1 to 3 substituents; R 3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6- membered ring which may be substituted with 1 to 3 C 1-6 alkyls; R 4 is a hydrogen, a halogen, a hydroxy, a cyano, a C 1-6 alkyl or a C 1-6 alkoxy; Z is -O-, -S-, -SO-, -SO 2 -, or - NR 5 - wherein R 5 is a hydrogen or a C 1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.

Abstract translation: 提供式（1）的化合物，其中R 1是任选取代的C 1-10烷基; R 2是H或可被1至3个取代基取代的C 1-6烷基; R 3是5或6元芳族基团，其可以被1至5个取代基取代，其中5或6元芳族基团可以与5-或6-元的 可以被1至3个C 1-6烷基取代的环; R 4是氢，卤素，羟基，氰基，C 1-6烷基或C 1-6烷氧基; Z是-O - ， - S - ， - SO - ， - SO 2 - 或-NR 5 - 其中R 5是 氢或C 1-6烷基; 或其盐或其前药，其具有CRF受体拮抗剂活性及其用途。

公开(公告)号：WO2008011131A3

公开(公告)日：2008-03-06

申请号：PCT/US2007016425

申请日：2007-07-20

Applicant: TAKEDA PHARMACEUTICAL ,  KITAMURA SHUJI ,  AICHER THOMAS DANIEL ,  GONZALES STEVE ,  LE HUEROU YVAN ,  PRATT SCOTT ALAN ,  TURNER TIM ,  NAKADA YOSHIHISA

Inventor： KITAMURA SHUJI ,  AICHER THOMAS DANIEL ,  GONZALES STEVE ,  LE HUEROU YVAN ,  PRATT SCOTT ALAN ,  TURNER TIM ,  NAKADA YOSHIHISA

IPC: C07D401/12

CPC classification number: C07D401/12 ,  C07D207/08 ,  C07D213/81 ,  C07D233/90 ,  C07D401/04 ,  C07D401/06 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/06 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides compounds represented by the formula (Ia) the formula (Ib) the formula (Ic) and the formula (Id) wherein each symbol is as defined in the specification. According to the present invention, these compounds have a DGAT inhibitory activity and are useful for the prophylaxis, treatment or improvement of diseases or pathologies caused by high expression or high activation of DGAT.

Abstract translation: 本发明提供由式（Ia）表示的化合物，式（Ib）式（Ic）和式（Id）的化合物，其中每个符号如说明书中所定义。 根据本发明，这些化合物具有DGAT抑制活性，可用于预防，治疗或改善由高表达或高活化DGAT引起的疾病或病理。

公开(公告)号：WO2006116412A8

公开(公告)日：2007-03-01

申请号：PCT/US2006015646

申请日：2006-04-26

Applicant: TAKEDA PHARMACEUTICAL ,  ASO KAZUYOSHI ,  GYOTEN MICHIYO ,  GYORKOS ALBERT CHARLES ,  CORRETTE CHRISTOPHER PETER ,  CHO SUK YOUNG ,  PRATT SCOTT ALAN ,  SIEDEM CHRISTOPHER STEPHEN

Inventor： ASO KAZUYOSHI ,  GYOTEN MICHIYO ,  GYORKOS ALBERT CHARLES ,  CORRETTE CHRISTOPHER PETER ,  CHO SUK YOUNG ,  PRATT SCOTT ALAN ,  SIEDEM CHRISTOPHER STEPHEN

IPC: C07D487/02

CPC classification number: C07D403/04 ,  C07D235/26 ,  C07D235/30 ,  C07D335/02 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D409/04 ,  C07D409/10 ,  C07D409/12 ,  C07D413/04 ,  C07D417/10 ,  C07D471/04 ,  C07D471/06 ,  C07D495/04

Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I) : wherein R1 is an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; R2 is an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or -NR3- (wherein R3 is a hydrogen, an optionally substituted hydrocarbyl or an acyl) ; Y1, Y2 and Y3 are each an optionally substituted carbon or a nitrogen, provided that one or less of Y1, Y2 and Y3 is nitrogen; and Z is a bond, -CO-, oxygen, sulfur, -SO-, -SO2-, -NR4-, -NR4-alk-, -CONR4- or -NR4CO- (wherein alk is an optionally substituted C3.-4 alkylene and R4 is a hydrogen, an optionally substituted hydrocarbyl or an acyl) ; or a salt thereof or a prodrug thereof .

Abstract translation: 提供了包含式（I）化合物的CRF受体拮抗剂：其中R1是任选取代的烃基，任选取代的C连接的杂环基，任选取代的N-连接的杂芳基，氰基或酰基; R2是任选取代的环状烃基或任选取代的杂环基; X是氧，硫或-NR 3 - （其中R 3是氢，任选取代的烃基或酰基）; Y1，Y2和Y3各自为任选取代的碳或氮，条件是Y1，Y2和Y3中的一个或多个为氮; 并且Z是键，-CO-，氧，硫，-SO - ， - SO 2 - ， - NR 4 - ， - NR 4 - 烷 - ， - CONR 4 - 或-NR 4 CO-（其中alk是任选取代的C 3 -4 亚烷基和R 4是氢，任选取代的烃基或酰基）; 或其盐或其前药。

公开(公告)号：WO2002020752A3

公开(公告)日：2002-03-14

申请号：PCT/US2001/026723

申请日：2001-08-27

Applicant: AVIGENICS, INC. Georgia Bio-Business Center ,  CHRISTMANN, Leandro ,  PRATT, Scott, L. ,  RAPP, Jeffrey, C.

Inventor： CHRISTMANN, Leandro ,  PRATT, Scott, L. ,  RAPP, Jeffrey, C.

IPC: C12N15/00

Abstract: Methods for producing cloned non-human animals by nuclear transfer and by combinations of nuclear transfer and ovum transfer, employing near-infrared visualization of the recipient cell nucleus are described herein. Transgenic, knock-out, and knock-in avians are provided. Method for producing eggs which contain exogenous proteins are encompassed by the present invention. Thus, the instant invention satisfies the need for an effective route to the generation of cloned avians.